Calidi Biotherapeutics Q2 EPS $(2.94) Down From $(1.99) YoY

Calidi Biotherapeutics Received NYSE American Notification Letter Regarding Stockholders’ Equity Deficiency

Calidi Biotherapeutics received a notice from NYSE American on September 21, 2026, indicating non-compliance with continued listing standards due to stockholders' equity deficiency of less than $4.0 million. The company has until October 21, 2026, to submit a compliance plan and must regain compliance by March 21, 2028, or face delisting proceedings. The company's stock will trade with a '.BC' designation indicating below-compliance status, though trading continues unaffected.

Calidi Biotherapeutics Receives NYSE American Non-Compliance Notice

Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or the "Company"), a biotechnology company pioneering the development of targeted genetic medicines, today announced that on September 21, 2026, the

Calidi Biotherapeutics shares are trading lower after the company announced a $1.2 million offering of 1,025,640 shares at $1.17 per share.

Calidi Biotherapeutics Announces Registered Direct Offering 1,025,640 Shares At $1.17 Per Share

The closing of the registered direct offering is expected to occur on or about September 18, 2026, subject to the satisfaction of customary closing conditions. The gross proceeds to Calidi from the registered direct